Skip to main
STTK

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs is a biotechnology company that has shown promising results with its lead drug, SL-325, targeting DR3 receptor for treating inflammatory bowel disease. The company's stock price has been adjusted based on its projected sales and valuation through clinical net present value model. Upcoming Phase 1 data for SL-325 is highly anticipated and is expected to contribute to a bullish outlook for the company, although potential risks still remain. Preclinical studies have shown positive results for SL-325, and its clinical trials will reveal its safety and efficacy. There is also potential for SL-325 to outperform other drugs targeting TL1A, depending on its immunogenicity and anti-drug antibodies.

Bears say

Shattuck Labs is facing strong competition in the field of developing DR3 inhibitors for IBD treatment, with promising results being shown by other companies such as XNCR's XmAb942. Additionally, while early studies have shown potential for SL-325, further research is needed to fully understand its efficacy and safety, and the company faces challenges in conducting successful clinical trials with varying primary endpoints and trial sizes. Overall, there is a level of uncertainty surrounding the success and market competitiveness of Shattuck Labs, leading to a negative outlook on the stock.

Shattuck Labs (STTK) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 5 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.